Showing 11-20 of 28 results for "".
- Health Canada Clears Cutera’s AviClearhttps://practicaldermatology.com/news/health-canada-clears-cuteras-aviclear/2461268/Health Canada has cleared Cutera, Inc.’s AviClear for the treatment of mild, moderate, and severe acne. This Health Canada announcement comes on the heels of the U.S. Food and Drug Administration’s 510(k) clearance of AviClear, in March 2022. In addition to reducing existing acne, clinical trial…
- Cutera Hosts AviClear Webinar This Weekhttps://practicaldermatology.com/news/cutera-hosts-aviclear-webinar-this-week/2461178/Cutera hosts the first webinar for AviClear, the first and only FDA cleared energy-based device for the treatment of mild, moderate, and severe acne, this week. Dermatologists Jeffrey S. Dover, MD, FRCPC and Julie C. Harper, MD will discuss the latest advancement in the treatment of acne and share…
- DERMWIRE Exclusive: FDA Clears Cutera’s AviClear Acne Devicehttps://practicaldermatology.com/news/dermwire-exclusive-fda-clears-cuteras-aviclear-acne-device/2461124/The U.S. Food and Drug Administration has cleared granted 510(k) clearance to Cutera’s AviClear acne device. This is the first energy device to receive a nod for the treatment of mild, moderate, and severe acne. AviClear targets acne at the source by selectively targeting the sebocytes and suppre…
- Dermavant: Posters Unveil Additional Data for Once-Daily Topical Tapinarofhttps://practicaldermatology.com/news/dermavant-posters-unveil-additional-data-for-once-daily-topical-tapinarof/2460770/Dermavant Sciences will present data in poster form from its two pivotal phase 3 trials for tapinarof for the treatment of psoriasis in adults, PSOARING 1 and PSOARING 2, at AAD VMX 2021. Tapinarof is a novel, once-daily therapeutic aryl hydrocarbon receptor modulating agent (TAMA). The posters fe…
- New from Solta: Meet the Next Generation Clear + Brilliant Laserhttps://practicaldermatology.com/news/new-from-solta-meet-the-next-generation-clear-brilliant-laser/2460711/Solta Medical is launching Clear + Brilliant Touch laser, the company’s next generation Clear + Brilliant laser. By seamlessly switching between two wavelengths with the Original and Perméa handpieces, physicians can now more easily deliver a more complete treatment during a single appointment. …
- New ASDS Guideline Addresses Prevention and Treatment of Filler Complicationshttps://practicaldermatology.com/news/new-asds-guideline-on-preventing-and-treating-filler-complications/2460685/The American Society for Dermatologic Surgery (ASDS) Multispecialty Soft-tissue Fillers Guideline Task Force has released its evidence-based recommendations for physicians performing injectable filler procedures including best practices for preventing and treating vascular occlusion, nodules, and o…
- For Upper Facial Lines, DaxibotulinumtoxinA Succeeds in Phase 2https://practicaldermatology.com/news/for-upper-facial-lines-daxibotulinumtoxina-succeeds-in-phase-2/2460637/Topline efficacy and safety results from the phase 2 multicenter, open-label study of Revance's investigational drug candidate DaxibotulinumtoxinA for Injection for the combined treatment of upper facial lines, show high levels of patient satisfaction. The 36-week study enrolled 48 subjects to rec…
- ASDS Announces On-demand Course for Dermatologists Planning to Take the New MDS Subspecialty Certification Examinationhttps://practicaldermatology.com/news/asds-announces-on-demand-course-for-dermatologists-planning-to-take-the-new-mds-subspecialty-certification-examination/2460598/To help board certified dermatologists prepare for the American Board of Dermatology’s (ABD) first ever Micrographic Dermatologic Surgery (MDS) Subspecialty Certification Examination next fall, the American Society for Dermatologic Surgery (ASDS) is offering the MDS Exam Review Course virtually thr…
- Ilumya Shows 5-Year Sustained Efficacy and Safety in Moderate-to-Severe Plaque Psoriasishttps://practicaldermatology.com/news/ilumya-shows-5-year-sustained-efficacy-and-safety-in-moderate-to-severe-plaque-psoriasis/2460596/Patients with moderate-to-severe plaque psoriasis who continued to receive Ilumya (tildrakizumab-asmn) through five years of continuous treatment maintained consistent and extensive skin clearance with no new safety signals, according to Phase 3 data from the combined reSURFACE 1 and reSURFACE 2 ex…
- Ovation Science Appoints Medical Dermatology Advisory Boardhttps://practicaldermatology.com/news/ovation-science-appoints-medical-dermatology-advisory-board/2460008/Ovation Science, Inc. has entered into an exclusive agreement with Skincareguide.com Ltd., to act as the Company's Medical Dermatology Advisory Board for cannabis formulated products. The objective of the Medical Dermatology Advisory Board is to provide guidance, along with clinical, scientific, re…